Bioconjugates for improved delivery of oligonucleotide therapeutics to the central nervous system [0.03%]
用于改善寡核苷酸药物向中枢神经系统递送的生物偶联物
Hye Jin Lee,Yunxuan Xie,Colin F Greineder et al.
Hye Jin Lee et al.
Oligonucleotide therapeutics, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), have gained increasing attention as a novel modality for gene-targeted interventions for central nervous system (CNS) disorders, ...
Optical imaging and spectroscopic characterization of subvisible particles in protein therapeutics [0.03%]
蛋白质药物中亚可见颗粒的光学影像及光谱表征研究进展
Brian S Wong,Jing Ling,Yongchao Su et al.
Brian S Wong et al.
The presence of subvisible particles in protein-based pharmaceutics is a critical quality attribute that is highly regulated due to potential risks to product stability, quality, bioavailability, and patient safety. While numerous analytica...
Jing Tan,Yuxin Liang,Shiqun Shao et al.
Jing Tan et al.
Targeted protein degradation (TPD) has revolutionized drug discovery by enabling the selective removal of specific proteins within and outside cells through the cell's natural degradation pathways. While various TPD modalities have demonstr...
Ann Badia,Jihyuk Yang,Sara Aliyeva et al.
Ann Badia et al.
Oral delivery of gas-based therapies provides a targeted, minimally invasive approach to treating oral diseases. Conventional strategies, such as mechanical debridement, antibiotics, and surgical intervention, are limited by the inaccessibi...
Harnessing targeted protein degradation to potentiate cancer immunotherapy: from molecular mechanisms to delivery strategies [0.03%]
利用靶向蛋白质降解增强癌症免疫治疗：从分子机制到输送策略
Ye Liu,Ihsan Ullah,Youyong Yuan et al.
Ye Liu et al.
Cancer immunotherapy is limited by immune escape, which is driven by overexpression of immunosuppressive proteins in the tumor microenvironment (TME). Targeted Protein Degradation (TPD) technology, utilizing cellular machinery to eliminate ...
Rational modification of PROTACs for tumor-selective protein degradation [0.03%]
合理改良PROTAC实现肿瘤选择性降解蛋白质功能
Zhongliang Fu,Meichen Pan,Chunrong Yang et al.
Zhongliang Fu et al.
Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules that hijack the ubiquitin-proteasome system to catalytically degrade pathogenic proteins. With the ability to target "undruggable" proteins and exert sustained pharma...
Biologics-device combinations: Enabling prolonged therapies in the posterior segment ocular disease [0.03%]
生物制剂-设备组合：在后部段眼部疾病中实现长期治疗
Shuqian Zhu,Jianjun Zhang,Xuling Jiang et al.
Shuqian Zhu et al.
Posterior segment ocular diseases (e.g., age-related macular degeneration and diabetic retinopathy, etc.) often necessitate frequent intravitreal (IVT) injections of biologics, due to the rapid drug clearance and formidable ocular barriers....
Genetic engineering approaches in stem and somatic cells for the generation of insulin-producing β-cells [0.03%]
基因工程在干细胞和体细胞中生成胰岛素产生β细胞中的应用
Abiramy Jeyagaran,Katja Schenke-Layland
Abiramy Jeyagaran
Cell replacement therapies hold great promise for the treatment of type 1 diabetes mellitus; however, the obtaining of sufficient transplantable β-cells limits the availability of this treatment option. The generation of β-cells from huma...
Quality by Computational Design: Harnessing AI to Advance Rational Drug Development [0.03%]
计算驱动的质量：利用人工智能推进理性新药研发
Nannan Wang,Hao Zhong,Ping Xiong et al.
Nannan Wang et al.
The pharmaceutical Quality by Design (QbD) principle aims to reduce risk and improve efficiency across drug development lifecycle. However, QbD was originally established in an era preceding the widespread adoption of artificial intelligenc...
Ella G Lambert,Sara Romanazzo,Peter L H Newman et al.
Ella G Lambert et al.
Human embryonic development is challenging to study in vitro as animal models inadequately represent human biology, while use of natural human embryos is both ethically and technically limited. Stem cell-based embryo models (SCBEMs) have em...